New cocktail aims to shrink advanced kidney tumors
NCT ID NCT05501054
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether combining three drugs—ipilimumab, nivolumab, and ciforadenant—can better control advanced kidney cancer that has spread. About 50 adults with clear cell renal cell carcinoma who have not had prior treatment will receive the combo. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab, nivolumab, and ciforadenant
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially improving tumor shrinkage rates.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply broadly. The three-drug combo may cause significant side effects, and it's unclear if it will outperform existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?